TPDs – Potential to Turn Undruggable to Druggable

Targeted Protein Degraders (TPDs) are pushing the boundaries of drug development by addressing previously untreatable targets. With 80% of TPDs in early stages, these therapies are reshaping the oncology landscape, especially with a focus on well-known targets and the aggressive development of selective estrogen receptor degraders (SERDs) for breast cancer.

Recent insights from Nature Reviews Drug Discovery and The Lancet Oncology highlight this growing focus and the increasing investment in TPDs for treating hard-to-target diseases. Promising efficacy data from PROTACs are bolstering confidence in TPDs, with projections suggesting that their market could reach USD 300 million by 2030, growing at a CAGR of 10.2%.

Drug developers are closely tracking efficacy, pharmacodynamic, and pharmacokinetic data, as TPDs demonstrate potential for providing durable target coverage with low doses. As these therapies gain momentum, they are poised to transform treatment approaches, offering innovative solutions for complex diseases.

Our infographic provides a comprehensive assessment of these advancements, offering you a forward-looking perspective on the latest TPD trends. Backed by analysis from our experts and globally recognized sources, it enables you to stay informed and explore how these cutting-edge therapies are shaping the future of precision medicine.

Contact our team to gain expert guidance on TPD investments and how they are shaping next-generation solutions in precision medicine.